The US Food and Drug
Administration (FDA) has approved
Adynovate, antihaemophilic factor
(recombinant), PEGylated for use
in adults and adolescents, aged
12 years and older, who have
Haemophilia A.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 17 Nov 15
To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Nov 15
